When does the Belsomra patent expire?
The patent for Belsomra, also known by its generic name suvorexant, is set to expire in 2027. This means that generic versions of the drug could become available after that date, potentially lowering costs for consumers [1].
What is Belsomra used for?
Belsomra is a medication prescribed to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It works by blocking the activity of orexin, a neurotransmitter that promotes wakefulness, thereby helping individuals fall asleep and stay asleep [3].
How does Belsomra compare to other insomnia medications?
Unlike older sleeping pills that act as sedatives, Belsomra targets the wakefulness system in the brain. This mechanism of action may offer a different approach to managing insomnia compared to drugs like benzodiazepines or Z-drugs, which directly depress the central nervous system [3].
What are the potential side effects of Belsomra?
Common side effects reported for Belsomra include drowsiness, dizziness, and headache. Less common but serious side effects can include abnormal dreams, anxiety, and hallucinations. Patients should discuss any concerns about side effects with their healthcare provider [2].
Who manufactures Belsomra?
Belsomra is manufactured by Merck & Co. [1].
Can generic Belsomra be manufactured before patent expiry?
Typically, generic drug manufacturers must wait for patent protection to expire before they can legally market their versions of a drug. However, patent litigation and challenges can sometimes lead to earlier market entry for generics [4]. DrugPatentWatch.com tracks these patent expirations and potential challenges [1].